Afuco™ Anti-Human DLL4 ADCC Therapeutic Antibody (MEDI0639), ADCC Enhanced
Anti-DLL4 ADCC Enhanced Antibody (MEDI0639) is an ADCC enhanced antibody produced by our Afuco™ platform. MEDI0639 is an investigational monoclonal antibody that selectively binds to Delta-like ligand 4 (DLL4) and blocks its ability to bind to and activate signaling through the Notch receptors, potentially inhibiting tumor growth by multiple mechanisms. Of 20 safety-evaluable pts, the most common treatment-related adverse events (trAEs) were increased aspartate aminotransferase, increased brain natriuretic peptide (BNP), and fatigue. No treatment-related deaths occurred. MEDI0639 150 mg did not exceed the MTD. Enrollment at the 200 mg dose level is ongoing. The safety profile is consistent with the mechanism of action and appears to be manageable. Preliminary evidence of antitumor activity was observed.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-205CL |
| Pricing | Inquiry |
| Host | Human |
| Target | DLL4 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Short term: store at 4°C (over 6 months), long term: -20°C or -80°C. |